Drug stocks split; Seattle Genetics dives
October 05, 2009 at 10:50 AM EDT
Drug stocks are split in early trading as shares of Seattle Genetics dive after the biotech group says it is halting a Phase II clinical study for its drug candidate dacetuzumab due to disappointing results.
